aTyr Pharma, Inc.

Stage 4 · Declining · week 6

As of Oct 22, 2026, aTyr Pharma is in Stage 4, the downtrend phase, now in week 6 (since Sep 15, 2026). It closed at $0.17, 83.8% below its 52-week high and below its 200-day average, which is falling.

$0.17

-0.41% today

$16.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ATYR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S2 35w

S2 15w

S4 19w

S4 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 21w → S1 8w → S2 7w → S3 6w → S2 1w → S3 5w → S2 35w → S3 9w → S2 15w → S3 3w → S4 19w → S1 11w → S4 16w → S1 4w → S4 5w current

Total tracked: 165 weeks across 15 stage runs.

ATYR among Biotechnology479th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…479	ATYRaTyr Pharma, Inc.	Stage 4 · wk 6	10	−54.7%

vs 52W High

-83.8%

$0.17 lo$1.05 hi

83.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-72.7%

200 DMA: $0.62 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.25x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-54.7%

-64.1%

-78.5%

YTD

-77.6%

-83.5%

Scan Membership

Breakout Watch

Latest: 2025-06-03

9 appearances in last 60 days. First seen: 2020-01-27.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 0.25x

2026-10-21S4

Wk 6 · Vol 0.30x

2026-10-20S4

Wk 6 · Vol 0.33x

2026-10-19S4

Wk 5 · Vol 0.53x

2026-10-16S4

Wk 5 · Vol 0.46x

2026-10-15S4

Wk 5 · Vol 0.57x

2026-10-14S4

Wk 5 · Vol 0.67x

2026-10-13S4

Wk 5 · Vol 0.69x

2026-10-12S4

Wk 4 · Vol 0.54x

2026-10-09S4

Wk 4 · Vol 0.26x

2026-10-08S4

Wk 4 · Vol 0.74x

2026-10-07S4

Wk 4 · Vol 0.30x

Moving averages & range

50 DMA

$0.38

200 DMA

$0.62

52W High

$1.05

52W Low

$0.17

5D Low

$0.17

Resistance levels (recent highs)

20d High

$0.31

60d High

$0.57

120d High

$1.04

250d High

$1.05

Next resistance

+81.2%

to 20d High

ROE

-98.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.3

aTyr Pharma: quick answers

What stage is aTyr Pharma in?

As of Oct 22, 2026, aTyr Pharma (ATYR) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 15, 2026 and is in week 6. What the four stages mean

Is aTyr Pharma in an uptrend?

No. aTyr Pharma is in a Stage 4 downtrend. It trades 72.7% below its 200-day average, which is falling.

How far is aTyr Pharma from its 52-week high?

aTyr Pharma closed at $0.17 on Oct 22, 2026, 83.8% below its 52-week high of $1.05. Its 52-week low is $0.17.

How has aTyr Pharma performed over the past year?

As of Oct 22, 2026, aTyr Pharma is down 83.5% over the past year and down 77.6% so far in 2026.

Which sector and industry is aTyr Pharma in?

aTyr Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.